Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peggy Manders

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Thrombosis and Haemostasis|February 26, 2004
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patientsPeggy Manders, Fred C G J Sweep, Vivianne C G Tjan-Heijnen, et al.
International Journal of Cancer|January 8, 2013
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer riskMadeleine M A Tilanus-Linthorst, Hester F Lingsma, D Gareth Evans, et al.
Breast Cancer Research and Treatment|August 24, 2010
Body weight and risk of breast cancer in BRCA1/2 mutation carriersPeggy Manders, Anouk Pijpe, Maartje J Hooning, et al.
Breast Cancer Research and Treatment|August 15, 2009
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriersAnouk Pijpe, Peggy Manders, Richard M Brohet, et al.
Gastroenterology|June 15, 2015
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1Rachel S van der Post, Ingrid P Vogelaar, Peggy Manders, et al.
BMJ (Clinical Research Ed.)|September 8, 2012
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)Anouk Pijpe, Nadine Andrieu, Douglas F Easton, et al.
Thrombosis and Haemostasis|September 6, 2003
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patientsMaxime Look, Wim van Putten, Michael Duffy, et al.
Journal of the National Cancer Institute|January 17, 2002
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patientsMaxime P Look, Wim L J van Putten, Michael J Duffy, et al.
Plos One|April 11, 2022
Correction: Protocol of the Healthy Brain Study: An accessible resource for understanding the human brain and how it dynamically and individually operates in its bio-social context, Esther Aarts, Agnes Akkerman, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Thrombosis and Haemostasis|February 26, 2004
The complex between urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently predicts response to first-line endocrine therapy in advanced breast cancerPeggy Manders, Vivianne C G Tjan-Heijnen, Paul N Span, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2003
Vascular endothelial growth factor independently predicts the efficacy of postoperative radiotherapy in node-negative breast cancer patientsPeggy Manders, Fred C G J Sweep, Vivianne C G Tjan-Heijnen, et al.
International Journal of Cancer|January 8, 2013
Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer riskMadeleine M A Tilanus-Linthorst, Hester F Lingsma, D Gareth Evans, et al.
Breast Cancer Research and Treatment|August 24, 2010
Body weight and risk of breast cancer in BRCA1/2 mutation carriersPeggy Manders, Anouk Pijpe, Maartje J Hooning, et al.
Breast Cancer Research and Treatment|August 15, 2009
Physical activity and the risk of breast cancer in BRCA1/2 mutation carriersAnouk Pijpe, Peggy Manders, Richard M Brohet, et al.
Gastroenterology|June 15, 2015
Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1Rachel S van der Post, Ingrid P Vogelaar, Peggy Manders, et al.
BMJ (Clinical Research Ed.)|September 8, 2012
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)Anouk Pijpe, Nadine Andrieu, Douglas F Easton, et al.
Thrombosis and Haemostasis|September 6, 2003
Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patientsMaxime Look, Wim van Putten, Michael Duffy, et al.
Journal of the National Cancer Institute|January 17, 2002
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patientsMaxime P Look, Wim L J van Putten, Michael J Duffy, et al.
Plos One|April 11, 2022
Correction: Protocol of the Healthy Brain Study: An accessible resource for understanding the human brain and how it dynamically and individually operates in its bio-social context, Esther Aarts, Agnes Akkerman, et al.
Pageof 4